Skip to main content
SpringerLink
Log in

Rejection and Immunosuppression

  • Chapter
  • First Online:
Textbook of Liver Transplantation

  • 1006 Accesses

Abstract

Historically, liver graft rejection has raised great interest in the scientific community since it was the major barrier to successful implementation of liver transplantation (LT) and to the achievement of long-term survival rates. Thanks to discovery and introduction of potent immunosuppressive agents—namely calcineurin inhibitors (CNI), cyclosporine (CsA), and tacrolimus (TAC)—, control of acute rejection (AR) of the liver graft has become feasible, and current clinical focus has shifted to chronic rejection (CR) and immunosuppressant-related side effects; these latter being responsible for a great proportion of the annual graft attrition rate.

Disclosures: Paolo De Simone has served as study scientific board member for Novartis, Astellas, and Chiesi, and has received speaker’s fees from Novartis, Astellas, and Chiesi. The other authors have no conflict of interest to declare.

Funding: None.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Morris PJ. Transplantation: a medical miracle of the 20th century. N Engl J Med. 2004;351(26):2678–80.

    CAS  PubMed  Google Scholar 

  2. Sayegh MH, Carpenter CB. Transplantation 50 years later: progress, challenges, and promises. N Engl J Med. 2004;351:2761–6.

    CAS  PubMed  Google Scholar 

  3. Borel JF, Feurer C, Gubler HU, et al. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions. 1976;6:468–75.

    CAS  PubMed  Google Scholar 

  4. Kino T, Hatanaka H, Miyata S, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo). 1987;40:1256–65.

    CAS  Google Scholar 

  5. Gourishankar S, Halloran PF. Late deterioration of organ transplants: a problem in injury and homeostasis. Curr Opin Immunol. 2002;14:576–83.

    CAS  PubMed  Google Scholar 

  6. Lodhi SA, Lamb KE, Meier-Kiesche HU. Solid organ allograft survival improvement in the United States: the long-term does not mirror dramatic short-term success. Am J Transplant. 2011;11(6):1226–35.

    CAS  PubMed  Google Scholar 

  7. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349(10):931–40.

    CAS  PubMed  Google Scholar 

  8. Watt KD, Charlton MR. Metabolic syndrome and liver transplantation: a review and guide to management. J Hepatol. 2010;53:199–206.

    PubMed  Google Scholar 

  9. Rubín A, Sánchez-Montes C, Aguilera V, Juan FS, Ferrer I, Moya A, et al. Long-term outcome of ‘long-term liver transplant survivors’. Transpl Int. 2013;26(7):740–50.

    PubMed  Google Scholar 

  10. D’Avola D, Cuervas-Mons V, Martí J, Ortiz de Urbina J, Lladó L, Jimenez C, et al. Cardiovascular morbidity and mortality after liver transplantation: the protective role of mycophenolate mofetil. Liver Transpl. 2017;3 https://doi.org/10.1002/lt.24738. [Epub ahead of print].

  11. Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Charlton MR. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant. 2010;10(6):1420–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Cozzi E, Colpo A, De Silvestro G. The mechanisms of rejection in solid organ transplantation. Transfus Apher Sci. 2017;56(4):498–505.

    PubMed  Google Scholar 

  13. Adams DH, Sanchez-Fueyo A, Samuel D. From immunosuppression to tolerance. J Hepatol. 2015;62(1 Suppl):S170–85.

    CAS  PubMed  Google Scholar 

  14. Higgins RM, Bevan DJ, Carey BS, Lea CK, Fallon M, Bühler R, et al. Prevention of hyperacute rejection by removal of antibodies to HLA immediately before renal transplantation. Lancet. 1996;348(9036):1208–11.

    CAS  PubMed  Google Scholar 

  15. Demetris AJ, Bellamy C, Hübscher SG, O'Leary J, Randhawa PS, Feng S, et al. Comprehensive update of the Banff Working Group on liver allograft pathology: introduction of antibody-mediated rejection. Am J Transplant. 2016;16(10):2816–35.

    CAS  PubMed  Google Scholar 

  16. Davis MM, Bjorkman PJ. T-cell antigen receptor genes and T-cell recognition. Nature. 1988;334:395–402.

    CAS  PubMed  Google Scholar 

  17. Viola A, Lanzavecchia A. T cell activation determined by T cell receptor number and tunable thresholds. Science. 1996;273:104–6.

    CAS  PubMed  Google Scholar 

  18. Chambers CA, Allison JP. Co-stimulation in T cell responses. Curr Opin Immunol. 1997;9:396–404.

    CAS  PubMed  Google Scholar 

  19. Larsen CP, Pearson TC. The CD40 pathway in allograft rejection, acceptance, and tolerance. Curr Opin Immunol. 1997;9:641–7.

    CAS  PubMed  Google Scholar 

  20. Toyokawa H, Nakao A, Bailey RJ, Nalesnik MA, Kaizu T, Lemoine JL, et al. Relative contribution of direct and indirect allorecognition in developing tolerance after liver transplantation. Liver Transpl. 2008;14(3):346–57.

    PubMed  PubMed Central  Google Scholar 

  21. Demetris AJ, Jaffe R, Tzakis A, et al. Antibody-mediated rejection of human orthotopic liver allografts. A study of liver transplantation across ABO blood group barriers. Am J Pathol. 1988;132:489–502.

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Gordon RD, Iwatsuki S, Esquivel CO, Tzakis A, Todo S, Starzl TE. Liver transplantation across ABO blood groups. Surgery. 1986;100:342–8.

    CAS  PubMed  Google Scholar 

  23. Doyle HR, Marino IR, Morelli F, et al. Assessing risk in liver transplantation. Special reference to the significance of a positive cytotoxic crossmatch. Ann Surg. 1996;224:168–77.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Nakamura K, Murase N, Becich MJ, et al. Liver allograft rejection in sensitized recipients. Observations in a clinically relevant small animal model. Am J Pathol. 1993;142:1383–91.

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Demetris AJ, Isse K. Tissue biopsy monitoring of operational tolerance in liver allograft recipients. Curr Opin Organ Transplant. 2013;18:345–53.

    CAS  PubMed  Google Scholar 

  26. Astarcioglu I, Cursio R, Reynes M, Gugenheim J. Increased risk of antibody-mediated rejection of reduced-size liver allografts. J Surg Res. 1999;87:258–62.

    CAS  PubMed  Google Scholar 

  27. Liu X, Xu J, Brenner DA, Kisseleva T. Reversibility of liver fibrosis and inactivation of fibrogenic myofibroblasts. Curr Pathobiol Rep. 2013;1:209–14.

    PubMed  PubMed Central  Google Scholar 

  28. Bellamy CO, Herriot MM, Harrison DJ, Bathgate AJ. C4d immunopositivity is uncommon in ABO-compatible liver allografts, but correlates partially with lymphocytotoxic antibody status. Histopathology. 2007;50:739–49.

    CAS  PubMed  Google Scholar 

  29. Smith RN, Colvin RB. Chronic alloantibody mediated rejection. Semin Immunol. 2012;24:115–21.

    CAS  PubMed  Google Scholar 

  30. Kozlowski T, Rubinas T, Nickeleit V, et al. Liver allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodies. Liver Transpl. 2011;17:357–68.

    PubMed  Google Scholar 

  31. Sebagh M, Castillo-Rama M, Azoulay D, et al. Histologic findings predictive of a diagnosis of de novo autoimmune hepatitis after liver transplantation in adults. Transplantation. 2013;96:670–8.

    CAS  PubMed  Google Scholar 

  32. Levitsky J, Feng S. Tolerance in clinical liver transplantation. Hum Immunol. 2018;79(5):283–7.

    CAS  PubMed  Google Scholar 

  33. Vionnet J, Sánchez-Fueyo A. Biomarkers of immune tolerance in liver transplantation. Hum Immunol. 2018;79(5):388–94.

    CAS  PubMed  Google Scholar 

  34. OPTN/SRTR Annual Data Report. http://srtr.transplant.hrsa.gov/annual_reports/2011/pdf/03_%20liver_12.pdf. Accessed 31 Jan 2019.

  35. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med. 2005;353:1711–23.

    CAS  PubMed  Google Scholar 

  36. Adam R, Karam V, Cailliez VO, Grady JG, Mirza D, Cherqui D, et al. 2018 Annual Report of the European Liver Transplant Registry (ELTR)—50-year evolution of liver transplantation. Transpl Int. 2018;31(12):1293–317.

    PubMed  Google Scholar 

  37. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation. 1995;60:225–32.

    CAS  PubMed  Google Scholar 

  38. Schuler W, Sedrani R, Cottens S, Haberlin B, Häberlin B, Schulz M, Schuurman HJ, et al. Sdz rad, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation. 1997;64:36–42.

    CAS  PubMed  Google Scholar 

  39. De Simone P, Nevens F, De Carlis L, Metselaar HJ, Beckebaum S, Saliba F, et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant. 2012;12:3008–20.

    PubMed  PubMed Central  Google Scholar 

  40. Shihab F, Christians U, Smith L, Wellen JR, Kaplan B. Focus on mtor inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes. Transpl Immunol. 2014;31:22–32.

    CAS  PubMed  Google Scholar 

  41. Hirose R. Pros and cons of using interleukin-2 receptor antibodies in liver transplant recipients. Liver Transpl. 2002;8(2):143–5.

    PubMed  Google Scholar 

  42. Benítez CE, Puig-Pey I, López M, Martínez-Llordella M, Lozano JJ, Bohne F, et al. ATG-Fresenius treatment and low-dose tacrolimus: results of a randomized controlled trial in liver transplantation. Am J Transplant. 2010;10(10):2296–304.

    PubMed  Google Scholar 

  43. Boudjema K, Camus C, Saliba F, Calmus Y, Salamé E, Pegeaux G, et al. Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study. Am J Transplant. 2011;11(5):965–76.

    CAS  PubMed  Google Scholar 

  44. Muduma G, Saunders R, Odeyemi I, Pollock RF. Systematic review and meta-analysis of tacrolimus versus cyclosporin as primary immunosuppression after liver transplant. PLoS One. 2016;11(11):e0160421.

    PubMed  PubMed Central  Google Scholar 

  45. Neuberger J, Mamelok RD, Neuhaus P, Pirenne J, Samuel D, Isoniemi H, et al. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the ‘ReSpECT’ study. Am J Transplant. 2009;9(2):327–36.

    CAS  PubMed  Google Scholar 

  46. Schnitzbauer AA, Sothmann J, Baier L, Bein T, Geissler EK, Scherer MN, Schlitt HJ. Calcineurin inhibitor free de novo immunosuppression in liver transplant recipients with pretransplant renal impairment: results of a pilot study (PATRON07). Transplantation. 2015;99(12):2565–75.

    CAS  PubMed  Google Scholar 

  47. Klintmalm GB, Feng S, Lake JR, Vargas HE, Wekerle T, Agnes S, et al. Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study. Am J Transplant. 2014;14(8):1817–27.

    CAS  PubMed  PubMed Central  Google Scholar 

  48. Goralczyk AD, Schnitzbauer A, Tsui TY, Ramadori G, Lorf T, Obed A. A therapeutic exploratory study to determine the efficacy and safety of calcineurin-inhibitor-free de-novo immunosuppression after liver transplantation: CILT. BMC Surg. 2010;10:15.

    PubMed  PubMed Central  Google Scholar 

  49. Manzia TM, Angelico R, Toti L, Belardi C, Cillis A, Quaranta C, et al. The efficacy and safety of mammalian target of rapamycin inhibitors ab initio after liver transplantation without corticosteroids or induction therapy. Dig Liver Dis. 2016;48(3):315–20. https://doi.org/10.1016/j.dld.2015.11.006.

    Article  CAS  PubMed  Google Scholar 

  50. Donckier V, Craciun L, Miqueu P, Troisi RI, Lucidi V, Rogiers X, et al. Expansion of memory-type CD8+ T cells correlates with the failure of early immunosuppression withdrawal after cadaver liver transplantation using high-dose ATG induction and rapamycin. Transplantation. 2013;96(3):306–15. https://doi.org/10.1097/TP.0b013e3182985414.

    Article  CAS  PubMed  Google Scholar 

  51. Rodríguez-Perálvarez M, Germani G, Papastergiou V, Tsochatzis E, Thalassinos E, Luong TV, et al. Early tacrolimus exposure after liver transplantation: relationship with moderate/severe acute rejection and long-term outcome. J Hepatol. 2013;58(2):262–70.

    PubMed  Google Scholar 

  52. Rodríguez-Perálvarez M, Germani G, Darius T, Lerut J, Tsochatzis E, Burroughs AK. Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta-analysis. Am J Transplant. 2012;12(10):2797–814.

    PubMed  Google Scholar 

  53. Nashan B, Saliba F, Durand F, Barcéna R, Herrero JI, Mentha G, et al. Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients. Liver Transpl. 2009;15(2):136–47.

    PubMed  Google Scholar 

  54. Lerut J, Mathys J, Verbaandert C, Talpe S, Ciccarelli O, Lemaire J, et al. Tacrolimus monotherapy in liver transplantation: one-year results of a prospective, randomized, double-blind, placebo-controlled study. Ann Surg. 2008;248(6):956–67.

    PubMed  Google Scholar 

  55. Asrani SK, Wiesner RH, Trotter JF, Klintmalm G, Katz E, Maller E, et al. De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial. Am J Transplant. 2014;14(2):356–66.

    CAS  PubMed  Google Scholar 

  56. Teperman L, Moonka D, Sebastian A, Sher L, Marotta P, Marsh C, et al. Spare-the-Nephron Trial Liver Transplantation Study Group. Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial. Liver Transpl. 2013;19(7):675–89.

    PubMed  Google Scholar 

  57. Saliba F, De Simone P, Nevens F, De Carlis L, Metselaar HJ, Beckebaum S, et al. Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study. Am J Transplant. 2013;13:1734–45.

    CAS  PubMed  Google Scholar 

  58. Fischer L, Saliba F, Kaiser GM, De Carlis L, Metselaar HJ, De Simone P, et al. Three-year outcomes in de novo liver transplant patients receiving everolimus with reduced tacrolimus: Follow-up results from a randomized, multicenter study. Transplantation. 2015;99:1455–62.

    CAS  PubMed  Google Scholar 

  59. Fischer L, Klempnauer J, Beckebaum S, Metselaar HJ, Neuhaus P, Schemmer P, et al. A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation—PROTECT. Am J Transplant. 2012;12:1855–65.

    CAS  PubMed  Google Scholar 

  60. Sterneck M, Kaiser GM, Heyne N, Richter N, Rauchfuss F, Pascher A, et al. Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a randomized trial in liver transplantation. Am J Transplant. 2014;14:701–10.

    CAS  PubMed  PubMed Central  Google Scholar 

  61. Sterneck M, Kaiser GM, Heyne N, Richter N, Rauchfuss F, Pascher A, et al. Long-term follow-up of five years shows superior renal function with everolimus plus early calcineurin inhibitor withdrawal in the PROTECT randomized liver transplantation study. Clin Transplant. 2016;30(6):741–8.

    CAS  PubMed  Google Scholar 

  62. Saliba F, Duvoux C, Gugenheim J, Kamar N, Dharancy S, Salamè E, et al. Efficacy and safety of everolimus and mycophenolic acid with early tacrolimus withdrawal after liver transplantation: A multicenter, randomized trial. Am J Transplant. 2017; https://doi.org/10.1111/ajt.14212. [Epub ahead of print].

  63. Lin M, Mittal S, Sahebjam F, Rana A, Kood GS. Everolimus with early withdrawal or reduced-dose calcineurin inhibitors improves renal function in liver transplant recipients: a systematic review and meta-analysis. Clin Transplant. 2017; https://doi.org/10.1111/ctr.12872. [Epub ahead of print]

  64. Cillo U, Saracino L, Vitale A, Bertacco A, Salizzoni M, Lupo F, et al. Very early introduction of everolimus in de novo liver transplantation: results of a multicenter, prospective, randomized Trial. Liver Transpl. 2019;25(2):242–51.

    PubMed  Google Scholar 

  65. De Simone P, Carrai P, Coletti L, Ghinolfi D, Petruccelli S, Precisi A, et al. Everolimus vs mycophenolate mofetil in combination with tacrolimus: a propensity score-matched analysis in liver transplantation. Transplant Proc. 2018;50(10):3615–20.

    PubMed  Google Scholar 

  66. Baroja-Mazo A, Revilla-Nuin B, Parrilla P, Martínez-Alarcón L, Ramírez P, Pons JA. Tolerance in liver transplantation: biomarkers and clinical relevance. World J Gastroenterol. 2016;22(34):7676–91.

    PubMed  PubMed Central  Google Scholar 

  67. Pons JA, Revilla-Nuin B, Ramírez P, Baroja-Mazo A, Parrilla P. Development of immune tolerance in liver transplantation. Gastroenterol Hepatol. 2011;34(3):155–69.

    PubMed  Google Scholar 

  68. Benítez C, Londoño MC, Miquel R, Manzia TM, Abraldes JG, Lozano JJ, et al. Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology. 2013;58:1824–35.

    PubMed  Google Scholar 

  69. Barkmann A, Nashan B, Schmidt HH, Böker KH, Emmanouilidis N, Rosenau J, et al. Improvement of acute and chronic renal dysfunction in liver transplant patients after substitution of calcineurin inhibitors by mycophenolate mofetil. Transplantation. 2000;69(9):1886–90.

    CAS  PubMed  Google Scholar 

  70. Schlitt HJ, Barkmann A, Böker KH, Schmidt HH, Emmanouilidis N, Roseanu J, et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomized controlled study. Lancet. 2001;357(9256):587–91.

    CAS  PubMed  Google Scholar 

  71. Pierini A, Mirabella S, Brunati A, Ricchiuti A, Franchello A, Salizzoni M. Mycophenolate mofetil monotherapy in liver transplantation. Transplant Proc. 2005;37(6):2614–5.

    CAS  PubMed  Google Scholar 

  72. Jiménez-Pérez M, Lozano Rey JM, Marín García D, Olmedo Martín R, de la Cruz LJ, Rodrigo López JM. Efficacy and safety of monotherapy with mycophenolate mofetil in liver transplantation. Transplant Proc. 2006;38(8):2480–1.

    PubMed  Google Scholar 

  73. Orlando G, Baiocchi L, Cardillo A, Iaria G, De Liguori CN, De Luca L. Switch to 1.5 grams MMF monotherapy for CNI-related toxicity in liver transplantation is safe and improves renal function, dyslipidemia, and hypertension. Liver Transpl. 2007;13(1):46–54.

    PubMed  Google Scholar 

  74. Barrera Pulido L, Alamo Martínez JM, Pareja Ciuró F, Gómez Bravo MA, Serrano-Díez-Canedo J, Bernal Bellido C, et al. Efficacy and safety of mycophenolate mofetil monotherapy in liver transplant patients with renal failure induced by calcineurin inhibitors. Transplant Proc. 2008;40(9):2985–7.

    CAS  PubMed  Google Scholar 

  75. Norero B, Serrano CA, Sanchez-Fueyo A, Duarte I, Torres A, Ocquetau M, et al. Conversion to mycophenolate mofetil monotherapy in liver recipients: calcineurin inhibitor levels are key. Ann Hepatol. 2017;16(1):94–106.

    CAS  PubMed  Google Scholar 

  76. De Simone P, Metselaar HJ, Fischer L, Dumortier J, Boudjema K, Hardwigsen J, et al. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial. Liver Transpl. 2009;15:1262–9.

    PubMed  Google Scholar 

  77. Saliba F, Dharancy S, Lorho R, Conti F, Radenne S, Neau-Cransac M, et al. Conversion to everolimus in maintenance liver transplant patients: a multicenter, retrospective analysis. Liver Transpl. 2011;17:905–13.

    PubMed  Google Scholar 

  78. De Simone P, Carrai P, Precisi A, Petruccelli S, Baldoni L, Balzano E, et al. Conversion to everolimus monotherapy in maintenance liver transplantation: feasibility, safety, and impact on renal function. Transpl Int. 2009;22:279–86.

    PubMed  Google Scholar 

  79. Abdelmalek MF, Humar A, Stickel F, Andreone P, Pascher A, Barroso E, et al. Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. Am J Transplant. 2012;12:694–705.

    CAS  PubMed  Google Scholar 

  80. Castroagudin JF, Molina E, Romero R, Otero E, Tome S, Varo E. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction. Liver Transpl. 2009;15:1792–7.

    PubMed  Google Scholar 

  81. De Simone P, Precisi A, Petruccelli S, Balzano E, Carrai P, Catalano G, et al. The impact of everolimus on renal function in maintenance liver transplantation. Transplant Proc. 2009;41:1300–2.

    PubMed  Google Scholar 

  82. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation. 2005;80:883–9.

    CAS  PubMed  Google Scholar 

  83. Yanik EL, Chinnakotla S, Gustafson SK, Snyder JJ, Israni AK, Segev DL, et al. Effects of maintenance immunosuppression with sirolimus after liver transplant for hepatocellular carcinoma. Liver Transpl. 2016;22(5):627–34.

    PubMed  PubMed Central  Google Scholar 

  84. De Simone P, Fagiuoli S, Cescon M, De Carlis L, Tisone G, Volpes R, et al. Consensus panel. Use of everolimus in liver transplantation: recommendations from a working group. Transplantation. 2017;101(2):239–51.

    PubMed  Google Scholar 

  85. Zhou J, Hu Z, Zhang Q, Li Z, Xiang J, Yan S, et al. Spectrum of de novo cancers and predictors in liver transplantation: analysis of the Scientific Registry of Transplant Recipients database. PLoS One. 2016;11(5):e0155179.

    PubMed  PubMed Central  Google Scholar 

  86. Rama I, Grinyó JM. Malignancy after renal transplantation: the role of immunosuppression. Nat Rev Nephrol. 2010;6(9):511–9.

    CAS  PubMed  Google Scholar 

  87. Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature. 1999;397(6719):530–4.

    CAS  PubMed  Google Scholar 

  88. Castello M, Gregorini M, Rampino T, Bosio F, Bedino G, Piotti G, et al. A retrospective analysis of dermatological lesions in kidney transplant patients. Indian J Med Res. 2013;137(6):1188–92.

    CAS  PubMed  PubMed Central  Google Scholar 

  89. Pendón-Ruiz de Mier V, Navarro Cabello MD, Martínez Vaquera S, Lopez-Andreu M, Aguera Morales ML, Rodriguez-Benot A, Aljama-Garcia P. Incidence and long-term prognosis of cancer after kidney transplantation. Transplant Proc. 2015;47(9):2618–21.

    PubMed  Google Scholar 

  90. Carenco C, Assenat E, Faure S, Duny Y, Danan G, Bismuth M, et al. Tacrolimus and the risk of solid cancers after liver transplant: a dose effect relationship. Am J Transplant. 2015;15(3):678–86.

    CAS  PubMed  Google Scholar 

  91. Crespo-Leiro MG, Alonso-Pulpón L, Vázquez de Prada JA, Almenar L, Arizón JM, Brossa V, et al. Malignancy after heart transplantation: incidence, prognosis and risk factors. Am J Transplant. 2008;8(5):1031–9.

    CAS  PubMed  Google Scholar 

  92. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002;8(2):128–35.

    CAS  PubMed  Google Scholar 

  93. Piselli P, Serraino D, Segoloni GP, Sandrini S, Piredda GB, Scolari MP, et al. Immunosuppression and Cancer Study Group, Risk of de novo cancers after transplantation: results from a cohort of 7217 kidney transplant recipients, Italy 1997-2009. Eur J Cancer. 2013;49(2):336–44.

    PubMed  Google Scholar 

  94. De Simone P, Carrai P, Coletti L, Ghinolfi D, Campani D, Filipponi F. Everolimus-based immunosuppression is associated with a reduced risk of new-onset malignancies after liver transplantation. Am J Transplant. 2015;15(Suppl 3):Abstract 1284.

    Google Scholar 

  95. Gomez-Camarero J, Salcedo M, Rincon D, Lo Iacono O, Ripoll C, Hernando A, et al. Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms. Transplantation. 2007;84(6):786–91.

    CAS  PubMed  Google Scholar 

  96. Thimonier E, Guillaud O, Walter T, Decuillier E, Vallin M, Boillot O, et al. Conversion to everolimus dramatically improves the prognosis of de novo malignancies after liver transplantation for alcoholic liver disease. Clin Transplant. 2014;28(12):1339–48.

    CAS  PubMed  Google Scholar 

  97. Bilbao I, Salcedo M, Gómez MA, Jimenez C, Castrogaudín J, Fabregat J, et al. EVEROLIVER study group. Renal function improvement in liver transplant recipients after early everolimus conversion: a clinical practice cohort study in Spain. Liver Transpl. 2015;21(8):1056–65.

    PubMed  Google Scholar 

  98. Yokoyama I, Carr B, Saitsu H, Iwatsuki S, Starzl TE. Accelerated growth rates of recurrent hepatocellular carcinoma after liver transplantation. Cancer. 1991;68(10):2095–100.

    CAS  PubMed  Google Scholar 

  99. Duvoux C, Toso C. mTOR inhibitor therapy: does it prevent HCC recurrence after liver transplantation. Transplant Rev. 2015;29(4):68–74.

    Google Scholar 

  100. Cholongitis E, Manou C, Rodriguez-Castro KI, Burra P. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review. Transpl Int. 2014;27(10):1039–49.

    Google Scholar 

  101. Junge G, Saliba F, De Simone P, Fischer L, Dong G, Speziale A, Fung J. Everolimus impact on hepatocellular carcinoma recurrence after liver transplantation—12, 24 and 36 months data from 719 liver transplant recipients. Am J Transplant. 2014;14(694):Abstract A376.

    Google Scholar 

  102. Ferreiro AO, Vazquez-Millán MA, López FS, Gutiérrez MG, Diaz SP, Patiño MG. Everolimus-based immunosuppression in patients with hepatocellular carcinoma at high risk of recurrence after liver transplantation: a case series. Transplant Proc. 2014;46(10):3496–501.

    CAS  PubMed  Google Scholar 

  103. Geissler EK, Schnitzbauer AA, Zulke C, Lamby PE, Proneth A, Duvoux C, et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial. Transplantation. 2016;101(1):116–25.

    Google Scholar 

  104. Shiah HS, Chen CY, Dai CY, Hsiao CF, Lin YJ, Su WC, et al. Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma. Alim Pharm Ther. 2013;37(1):62–73.

    CAS  Google Scholar 

  105. Zhu AX, Abrams TA, Miksad R, Blaszkowsky LS, Meyehardt JA, Zheng H, et al. Phase 1/2 study of everolimus in advanced hepatocellular cancer. Cancer. 2011;117(22):5094–102.

    CAS  PubMed  Google Scholar 

  106. Yamanaka K, Petrulionis M, Lin S, Gao C, Galli U, Richter S, et al. Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma—systematic review and meta-analysis. Cancer Med. 2013;2(6):862–71.

    CAS  PubMed  PubMed Central  Google Scholar 

  107. Zhu AX, Kudo M, Assenat E, Cattan S, Kang YK, Lim HY, et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA. 2014;312(1):57–67.

    PubMed  Google Scholar 

  108. De Simone P, Crocetti L, Pezzati D, Bargellini I, Ghinolfi D, Carrai P, et al. Efficacy and safety of combination therapy with everolimus and sorafenib for recurrence of hepatocellular carcinoma after liver transplantation. Transplant Proc. 2014;46(2):241–4.

    PubMed  Google Scholar 

  109. Valdivieso A, Bustamante J, Gastaca M, Uriarte JG, Ventoso A, Ruiz P, et al. Management of hepatocellular carcinoma recurrence after liver transplantation. Transplant Proc. 2010;42(2):660–2.

    CAS  PubMed  Google Scholar 

  110. Gomez-Martin C, Bustamante J, Castroagudín JF, Salcedo M, Garralda E, Testillano M, et al. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl. 2012;18(1):45–52.

    PubMed  Google Scholar 

  111. Umbro I, Tinti F, Scalera I, Evison F, Gunson B, Sharif A, et al. Acute kidney injury and post-reperfusion syndrome in liver transplantation. World J Gastroenterol. 2016;22(42):9314–23.

    CAS  PubMed  PubMed Central  Google Scholar 

  112. Gonwa TA. Treatment of renal dysfunction after orthotopic liver transplantation: options and outcomes. Liver Transpl. 2003;9(7):778–9.

    PubMed  Google Scholar 

  113. Bechstein WO. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transpl Int. 2000;13(5):313–26.

    CAS  PubMed  Google Scholar 

  114. Campagna F, Biancardi A, Cillo U, Gatta A, Amodio P. Neurocognitive-neurological complications of liver transplantation: a review. Metab Brain Dis. 2010;25(1):115–24.

    PubMed  Google Scholar 

  115. Catalano G, De Simone P, Mazzoni A, Ghinolfi D, Coletti L, Filipponi F. Everolimus-based immunosuppression in a case of ABO-incompatible liver transplantation with calcineurin inhibitor-related posterior occipital syndrome. Transpl Int. 2014;27(9):84–6.

    Google Scholar 

  116. Chakkera HA, Kudva Y, Kaplan B. Calcineurin inhibitors: pharmacologic mechanisms impacting both insulin resistance and insulin secretion leading to glucose dysregulation and diabetes mellitus. Clin Pharmacol Ther. 2017;101(1):114–20. https://doi.org/10.1002/cpt.546. Epub 2016 Nov 21

    Article  CAS  PubMed  Google Scholar 

  117. Gosmanov AR, Dagogo-Jack S. Predicting, managing and preventing new-onset diabetes after transplantation. Minerva Endocrinol. 2012;37(3):233–46.

    CAS  PubMed  Google Scholar 

  118. Marchetti P. New-onset diabetes after liver transplantation: from pathogenesis to management. Liver Transpl. 2005;11(6):612–20.

    PubMed  Google Scholar 

  119. Lorho R, Hardwigsen J, Dumortier J, Pageaux GP, Durand F, Bizollon T, et al. Regression of new-onset diabetes mellitus after conversion from tacrolimus to cyclosporine in liver transplant patients: results of a pilot study. Clin Res Hepatol Gastroenterol. 2011;35(6-7):482–8.

    CAS  PubMed  Google Scholar 

  120. Fine NM, Kushwaha SS. Recent advances in mammalian target of rapamycin inhibitor use in heart and lung transplantation. Transplantation. 2016;100(12):2558–68.

    CAS  PubMed  Google Scholar 

  121. Santos CA, Hotchkiss RS, Chapman WC, Olsen MA. Epidemiology of bloodstream infections in a multicenter retrospective cohort of liver transplant recipients. Transplant Direct. 2016;2(3):e67. https://doi.org/10.1097/TXD.0000000000000573. eCollection 2016.

    Article  PubMed  PubMed Central  Google Scholar 

  122. Abad CL, Lahr BD, Razonable RR. Epidemiology and risk factors for infection after living donor liver transplantation. Liver Transpl. 2017; https://doi.org/10.1002/lt.24739. [Epub ahead of print]

  123. Martin-Gandul C, Stampf S, Héquet D, Mueller NJ, Cusini A, van Delden C, et al. Swiss Transplant Cohort Study (STCS). Preventive strategies against cytomegalovirus and incidence of α-Herpesvirus infections in solid organ transplant recipients: a nationwide cohort study. Am J Transplant. 2016;31 https://doi.org/10.1111/ajt.14192. [Epub ahead of print].

  124. Radtke J, Dietze N, Spetzler VN, Fischer L, Achilles EG, Li J, et al. Fewer cytomegalovirus complications after kidney transplantation by de novo use of mTOR inhibitors in comparison to mycophenolic acid. Transpl Infect Dis. 2016;18(1):79–88.

    CAS  PubMed  Google Scholar 

  125. Chiu LM, Domagala BM, Park JM. Management of opportunistic infections in solid-organ transplantation. Prog Transplant. 2004;14(2):114–29.

    PubMed  Google Scholar 

  126. Pascual J, Royuela A, Fernández AM, Herrero I, Delgado JF, Solé A, et al. Spanish society of transplantation virological and immune response investigation study group. Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients. Transpl Infect Dis. 2016;18(6):819–31.

    CAS  PubMed  Google Scholar 

  127. Winsett RP, Stratta RJ, Alloway R, Wicks MN, Hathaway DK. Immunosuppressant side effect profile does not differ between organ transplant types. Clin Transplant. 2001;15(Suppl 6):46–50.

    PubMed  Google Scholar 

  128. Lucan VC, Berardinelli L. Gastrointestinal side effects of post-transplant therapy. J Gastrointestin Liver Dis. 2016;25(3):367–73.

    PubMed  Google Scholar 

  129. Sterneck M, Settmacher U, Ganten T, Sarrazin C, Speidel N, Broering D, et al. Improvement in gastrointestinal and health-related quality of life outcomes after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant recipients. Transplant Proc. 2014;46(1):234–40.

    CAS  PubMed  Google Scholar 

  130. Holdaas H, Potena L, Saliba F. mTOR inhibitors and dyslipidemia in transplant recipients: a cause for concern? Transplant Rev (Orlando). 2015;29(2):93–102.

    Google Scholar 

  131. Saliba F, Rostaing L, Gugenheim J, Durand F, Radenne S, Leroy V, et al. Corticosteroid-sparing and optimization of mycophenolic acid exposure in liver transplant recipients receiving mycophenolate mofetil and tacrolimus: a randomized, multicenter study. Transplantation. 2016;100(8):1705–13.

    CAS  PubMed  Google Scholar 

  132. Ferté C, Paci A, Zizi M, Gonzales DB, Goubar A, Gomez-Roca C, et al. Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues. Eur J Cancer. 2011;47(15):2249–55.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hepatobiliary Surgery and Liver Transplantation, University of Pisa Medical School Hospital, Pisa, Italy

    Paolo De Simone & Jessica Bronzoni

  2. Intensive Care Unit, University of Pisa Medical School Hospital, Pisa, Italy

    Maria Lucia Bindi

Authors
  1. Paolo De Simone
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jessica Bronzoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maria Lucia Bindi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paolo De Simone .

Editor information

Editors and Affiliations

  1. Department of Surgery, Oncology, and Gastroenterology Mutltivisceral Transplant Unit, University of Padua, Padua, Italy

    Patrizia Burra

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

De Simone, P., Bronzoni, J., Bindi, M.L. (2022). Rejection and Immunosuppression. In: Burra, P. (eds) Textbook of Liver Transplantation. Springer, Cham. https://doi.org/10.1007/978-3-030-82930-8_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-82930-8_17

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-82929-2

  • Online ISBN: 978-3-030-82930-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation